問卷

TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of Thoracic Medicine

Division of General Internal Medicine

Division of Infectious Disease

更新時間:2024-06-13

黃偉彰Huang, Wei- Chang
  • Principal Investigator
  • Clinical Trial Experience (year)
  • huangweichangtw@gmail.com

篩選

List

28Cases

2025-10-01 - 2028-12-31

Active
A phase 2b, randomized, double-blind, placebo-controlled, parallel, multiple-dose trial was conducted to evaluate the efficacy, safety, and pharmacokinetics of AZD0292 in patients aged 12 years and older with bronchiectasis and chronic Pseudomonas aeruginosa grafts.
  • Condition/Disease

    In NCFBE and chronic PsA transfer subjects, the effect of AZD0292 IV every 4 weeks (Q4W) compared with placebo on the incidence of moderate to severe acute lung exacerbations was evaluated.

  • Test Drug

    AZD0292

Participate Sites
7Sites

Recruiting7Sites

2019-10-01 - 2023-04-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting4Sites

Terminated1Sites

2012-05-30 - 2013-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2013-07-01 - 2015-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2014-06-01 - 2015-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2010-08-30 - 2012-09-30

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2023-02-01 - 2024-11-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2025-10-20 - 2030-07-11

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2025-10-01 - 2027-10-01

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2022-09-30 - 2026-04-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

1 2 3